Journal issue overview 12/2018 Internal Medicine

1124

A summary of the EAS consensus concerning the causal relationship between low-density lipoproteins and atherosclerotic cardiovascular diseases, prepared by the Board of the Czech Society for Atherosclerosis

Vladimír Soška, David Karásek, Vladimír Bláha, Renata Cífková, Tomáš Freiberger, Pavel Kraml, Jan Piťha, Hana Rosolová, Tomáš Štulc, Zuzana Urbanová, Michal Vrablík

1131

Consensus statement of professional associations on prescribing of PCSK9-inhibitors

Richard Češka, Miloš Táborský, Michal Vrablík

1137

Comments on the most important and recent studies involving PCSK9i

Richard Češka

1142

Inflammation and atherosclerosis

Rudolf Poledne, Ivana Králová Lesná

1148

Bilirubin: from an unimportant waste product to important myocardial infarction predictor

Jaroslav A. Hubáček, Libor Vítek

1153

“The higher the better” seems to be no longer true for HDL-cholesterol

Hana Rosolová

1156

Current views on metabolic syndrome

Štěpán Svačina

1160

Lipoprotein(a) – the cardiovascular risk factor: significance and therapeutic possibilities

Vladimír Bláha

1169

Why not to interfere with LDL-cholesterol freefall and why not to talk badly about statins

Jan Piťha

1177

Combined lipid-lowering therapy

David Karásek

1186

PCSK9 inhibitors and diabetes mellitus

Branislav Vohnout, Jana Lisičanová, Andrea Havranová

1190

The changes in cardiovascular prevention practice between 1995–2017 in the Czech Republic: a comparison of EUROASPIRE I, II, III, IV and V study

Otto Mayer Jr, Jan Bruthans, Martina Rychecká Za Investigátory Studií Euroaspire I V V České Republice

Internal Medicine - Issue 12/2018

Guidelines

News

Actualities

Original Contributions

Internal Medicine